Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga PSMA-11 PET/CT in Prostate Cancer Recurrence
NCT04483414Phase 2Withdrawn
- Start
- Mar 2021
- Primary completion
- Apr 2023
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial. Primary endpoints: Location of recurrence at 3 years and Residual prostate cancer at 3 years. Planned start Mar 2021; status: withdrawn.
Beyond the preview
Go deeper on NCT04483414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04483414.